NCT05113511 - PK and Safety of SCT510 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 9, 2018

Primary Completion Date

November 28, 2018

Study Completion Date

July 26, 2021

Conditions

Healthy

Interventions

DRUG

SCT510

Subjects received a single intravenous infusion (3 mg/kg) of SCT510 for 90 minutes , and the volume of administration was calculated based on the subject's weight.

DRUG

Bevacizumab

Subjects received a single intravenous infusion (3 mg/kg) of bevacizumab for 90 minutes , and the volume of administration was calculated based on the subject's weight.

Trial Locations (1)

310003

First Affiliated Hospital of Zhejiang University, Hangzhou

All Listed Sponsors

collaborator

Sinocelltech Ltd.

INDUSTRY

lead

First Affiliated Hospital of Zhejiang University

OTHER